Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Manisha Palta, MD, Duke University Cancer Center
Videos
An Argument for Radiation in the Neoadjuvant Setting for Pancreatic Cancer
03/23/2023
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation...
03/23/2023
Oncology
Gerard Morton, MD, Odette Cancer Center at Sunnybrook Research Institute
Videos
Methods of Radiation Dose Intensification for High-Risk Prostate Cancer
03/21/2023
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation...
03/21/2023
Oncology
Mylin Torres, MD, Winship Cancer Institute
Videos
Five-Fraction Radiation Regimens for Early-Stage Breast Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
Chemoimmunotherapy and the Changing Landscape of Preoperative Treatment for Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
How Preoperative Chemoimmunotherapy May Change Management of Patients With Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Quiz
Quiz: Does Metoformin, CCRT Combo Improve OS in NSCLC?
03/30/2022
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a...
03/30/2022
Oncology
Adding Metformin to CCRT Does Not Improve Survival in NSCLC
03/23/2022
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to...
03/23/2022
Oncology
Quiz
Quiz: Does Nivolumab Impact Surgical Outcomes in Residual Disease?
03/16/2022
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at...
03/16/2022
Oncology
elderly screening patient
Quiz
Novel MS-VMAT Technique for Whole Lung Irradiation
03/15/2022
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology
Dr Chuong
Videos
Dr Chuong Highlights Ablative MR-Guided Radiation Therapy in Inoperable Pancreatic Cancer
10/04/2021
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer...
10/04/2021
Oncology
Quiz
Quiz: Dose Escalation in Esophageal Cancer
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
Interview
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
01/28/2020
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS,...
01/28/2020
Oncology

Advertisement

Advertisement

At the Radiation Oncology Summit: ACRO, attendees can learn about the latest research updates in radiation oncology and network with like-minded colleagues in the radiology space.

What Your Colleagues are Reading

News
Ivonescimab Projected to Treat EGFR-TKI Resistant, Advanced NSCLC
02/04/2022
A phase 3 trial projects substantial antitumor effect with ivonescimab in patients with EGFR-TKI resistant, advanced, or metastatic NSCLC with an EGFR mutation.
A phase 3 trial projects substantial antitumor effect with ivonescimab in patients with EGFR-TKI resistant, advanced, or metastatic NSCLC with an EGFR mutation.
A phase 3 trial projects...
02/04/2022
Oncology
News
Researchers Identify DKK3 as a Novel Biomarker for Post-Transplant cGVHD
07/21/2020
Study findings suggest that an association exists between plasma DKK3 concentrations and nonrelapse mortality in patients with cGVHD.
Study findings suggest that an association exists between plasma DKK3 concentrations and nonrelapse mortality in patients with cGVHD.
Study findings suggest that an...
07/21/2020
Oncology
News
Disease Progression is Major Cause of Treatment Failure After HCT in Transformed FL
02/22/2022
A retrospective study has characterized the outcomes of patients with transformed FL who underwent HCT.
A retrospective study has characterized the outcomes of patients with transformed FL who underwent HCT.
A retrospective study has...
02/22/2022
Oncology
News
FDA Approves Oral Decitabine–Cedazuridine Combo for Adults With MDS
07/07/2020
The FDA has approved an oral combination of decitabine and cedazuridine for the treatment of adults with MDS.
The FDA has approved an oral combination of decitabine and cedazuridine for the treatment of adults with MDS.
The FDA has approved an oral...
07/07/2020
Oncology
News
Tisagenlecleucel Shows Similar Effects to Standard Care for DLBCL
02/28/2022
In an international phase 3 trial, second-line tisagenlecleucel was not superior to salvage therapy for refractory DLBCL.
In an international phase 3 trial, second-line tisagenlecleucel was not superior to salvage therapy for refractory DLBCL.
In an international phase 3...
02/28/2022
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement